• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性阻塞性肺疾病(COPD)患者的嗜酸性粒细胞计数与治疗反应

Eosinophil count and treatment response in COPD patients.

作者信息

Kiran C R, Kumari K Anitha, Nair Sanjeev, Fathahudeen A

机构信息

Department of Pulmonary Medicine, Government Medical College, Thiruvananthapuram, Kerala, India.

Department of Pulmonary Medicine, Government Medical College, Ernakulam, Kerala, India.

出版信息

Lung India. 2025 Jul 1;42(4):337-342. doi: 10.4103/lungindia.lungindia_630_24. Epub 2025 Jun 27.

DOI:10.4103/lungindia.lungindia_630_24
PMID:40569402
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12342202/
Abstract

BACKGROUND AND OBJECTIVE

Eosinophils are an integral part of lung defence against microbes. It is also responsible for untoward hyper immune responses responsible for lung diseases including Chronic Obstructive Pulmonary Disease (COPD). To compare COPD patients with high and low Absolute Eosinophil Count (AEC) regarding their frequency of exacerbations, and response to treatment.

MATERIALS AND METHODS

Prospective observational study. Patients were divided into 2 groups above and below the mean AEC and followed up for 6 months, during when their frequencies of exacerbations were followed up. At the end of 6 months, symptomatology and lung function were reassessed.

RESULTS

Those with high AEC had a shorter time to first exacerbation. These patients also needed significantly greater number of inpatient admissions during the study period. Fall in FEV1 was also significantly higher in this group. There was no significant difference in changes in BMI, CAT or MMRC scores, between these groups.

CONCLUSION

Patients with high AEC are at higher risk of exacerbations, as well as loss of lung function.

摘要

背景与目的

嗜酸性粒细胞是肺部抵御微生物的重要组成部分。它也会引发不良的过度免疫反应,导致包括慢性阻塞性肺疾病(COPD)在内的肺部疾病。比较绝对嗜酸性粒细胞计数(AEC)高和低的COPD患者的急性加重频率以及对治疗的反应。

材料与方法

前瞻性观察性研究。将患者按AEC均值分为两组,随访6个月,期间跟踪其急性加重频率。6个月末,重新评估症状和肺功能。

结果

AEC高的患者首次急性加重的时间较短。在研究期间,这些患者的住院次数也显著更多。该组的第一秒用力呼气容积(FEV1)下降也显著更高。两组之间的体重指数(BMI)、慢性阻塞性肺疾病评估测试(CAT)或改良英国医学研究委员会(MMRC)评分变化无显著差异。

结论

AEC高的患者急性加重风险更高,肺功能丧失风险也更高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff70/12342202/632af824b1f3/LI-42-337-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff70/12342202/632af824b1f3/LI-42-337-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff70/12342202/632af824b1f3/LI-42-337-g001.jpg

相似文献

1
Eosinophil count and treatment response in COPD patients.慢性阻塞性肺疾病(COPD)患者的嗜酸性粒细胞计数与治疗反应
Lung India. 2025 Jul 1;42(4):337-342. doi: 10.4103/lungindia.lungindia_630_24. Epub 2025 Jun 27.
2
Sputum colour charts to guide antibiotic self-treatment of acute exacerbation of chronic obstructive pulmonary disease: the Colour-COPD RCT.用于指导慢性阻塞性肺疾病急性加重期抗生素自我治疗的痰液颜色图表:Colour-COPD随机对照试验
Health Technol Assess. 2025 May;29(28):1-42. doi: 10.3310/KPFD5558.
3
Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.用于囊性纤维化患者肺部加重期的静脉用抗生素
Cochrane Database Syst Rev. 2025 Jan 20;1(1):CD009730. doi: 10.1002/14651858.CD009730.pub3.
4
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].[支气管哮喘防治指南(2024年版)]
Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601.
5
Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.慢性阻塞性肺疾病患者自我管理干预措施(包括针对病情加重的行动计划)与常规护理的比较。
Cochrane Database Syst Rev. 2017 Aug 4;8(8):CD011682. doi: 10.1002/14651858.CD011682.pub2.
6
Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.吸入性皮质类固醇联合吸入长效β2-激动剂和长效抗胆碱能药物治疗慢性阻塞性肺疾病。
Cochrane Database Syst Rev. 2023 Dec 6;12(12):CD011600. doi: 10.1002/14651858.CD011600.pub3.
7
Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.噻托溴铵与异丙托溴铵治疗慢性阻塞性肺疾病的比较
Cochrane Database Syst Rev. 2015 Sep 22;2015(9):CD009552. doi: 10.1002/14651858.CD009552.pub3.
8
Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.噻托溴铵与异丙托溴铵治疗慢性阻塞性肺疾病的比较
Cochrane Database Syst Rev. 2013 Sep 16(9):CD009552. doi: 10.1002/14651858.CD009552.pub2.
9
Long-acting beta2-agonists for chronic obstructive pulmonary disease.用于慢性阻塞性肺疾病的长效β2受体激动剂。
Cochrane Database Syst Rev. 2013 Oct 15;2013(10):CD010177. doi: 10.1002/14651858.CD010177.pub2.
10
Vitamin D for the management of chronic obstructive pulmonary disease.维生素D用于慢性阻塞性肺疾病的管理
Cochrane Database Syst Rev. 2024 Sep 27;9(9):CD013284. doi: 10.1002/14651858.CD013284.pub2.

本文引用的文献

1
Comparison of Risk of Pneumonia Caused by Fluticasone Propionate versus Budesonide in Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study.丙酸氟替卡松与布地奈德治疗慢性阻塞性肺疾病致肺炎风险的比较:一项全国性回顾性队列研究。
Int J Chron Obstruct Pulmon Dis. 2021 Nov 25;16:3229-3237. doi: 10.2147/COPD.S332151. eCollection 2021.
2
Upper airway symptoms associate with the eosinophilic phenotype of COPD.上气道症状与慢性阻塞性肺疾病的嗜酸性粒细胞表型相关。
ERJ Open Res. 2021 Aug 2;7(3). doi: 10.1183/23120541.00184-2021. eCollection 2021 Jul.
3
Blood Eosinophils and Clinical Outcomes in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Propensity Score Matching Analysis of Real-World Data in China.
慢性阻塞性肺疾病急性加重患者的血液嗜酸性粒细胞与临床结局:中国真实世界数据的倾向评分匹配分析
Front Med (Lausanne). 2021 Jun 9;8:653777. doi: 10.3389/fmed.2021.653777. eCollection 2021.
4
Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD.吸入性糖皮质激素治疗慢性阻塞性肺疾病的长期不良反应的系统评价
Eur Respir Rev. 2021 Jun 23;30(160). doi: 10.1183/16000617.0075-2021. Print 2021 Jun 30.
5
Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait.COPD 中的嗜酸性粒细胞炎症:从炎症标志物到可治疗的特征。
Thorax. 2021 Feb;76(2):188-195. doi: 10.1136/thoraxjnl-2020-215167. Epub 2020 Oct 29.
6
Risk of Pneumonia with Different Inhaled Corticosteroids in COPD Patients: A Meta-Analysis.不同吸入性皮质类固醇治疗 COPD 患者的肺炎风险:一项荟萃分析。
COPD. 2020 Aug;17(4):462-469. doi: 10.1080/15412555.2020.1787369. Epub 2020 Jul 9.
7
COPD treatment choices based on blood eosinophils: are we there yet?基于血液嗜酸性粒细胞的慢性阻塞性肺疾病治疗选择:我们做到了吗?
Breathe (Sheff). 2019 Dec;15(4):318-323. doi: 10.1183/20734735.0254-2019.
8
Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial.嗜酸粒细胞指导下的 COPD 加重住院患者的皮质类固醇治疗(CORTICO-COP):一项多中心、随机、对照、开放标签、非劣效性试验。
Lancet Respir Med. 2019 Aug;7(8):699-709. doi: 10.1016/S2213-2600(19)30176-6. Epub 2019 May 20.
9
Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials.慢性阻塞性肺疾病患者加重风险和布地奈德治疗反应的预测因素:三项随机试验的事后分析。
Lancet Respir Med. 2018 Feb;6(2):117-126. doi: 10.1016/S2213-2600(18)30006-7. Epub 2018 Jan 10.
10
FEV Decline in Patients with Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病患者的第一秒用力呼气容积下降
Am J Respir Crit Care Med. 2017 Jun 15;195(12):1676-1677. doi: 10.1164/rccm.201701-0001LE.